Biosimilar Newsletter Archive

1. 06.25.26 -- What To Do About Process Drift In Your Biosimilar's Reference Product 6/25/2026
   06/25/26 Biosimilar Development Newsletter
2. 06.18.26 -- Reduce mAb Aggregates: Practical Strategies 6/18/2026

   06/18/26 Biosimilar Development Newsletter

3. 06.18.26 -- Will FDA's One-Day Inspection Pilot Stand The Test Of Time? 6/18/2026
   06/18/26 Biosimilar Development Newsletter
4. 06.11.26 -- Process Intensification: Your Guide To "Doing More With Less" 6/11/2026
   06/11/26 Biosimilar Development Newsletter
5. 06.04.26 -- Are Biotechs Wasting Time On The Wrong CDMO? 6/4/2026
   06/04/26 Biosimilar Development Newsletter
6. 05.21.26 -- Minimizing Regulatory Risk For Biologics Manufacturing Changes 5/21/2026
   05/21/26 Biosimilar Development Newsletter
7. 05.14.26 -- Do Changes Signal The End Of Biosimilar Regulatory Redundancy? 5/14/2026
   05/14/26 Biosimilar Development Newsletter
8. 05.07.26 -- The Business Case For Continuous Manufacturing In Biologics 5/7/2026
   05/07/26 Biosimilar Development Newsletter
9. 04.30.26 -- Quantifying Single-Use Waste Produced During mAb Manufacture 4/30/2026
   04/30/26 Biosimilar Development Newsletter
10. 04.16.26 -- Innovation That's Redefining Aseptic Filling 4/16/2026
    04/16/26 Biosimilar Development Newsletter